Alterity Therapeutics Limited (PRNAF)
- Previous Close
0.0036 - Open
0.0036 - Bid 0.0018 x --
- Ask 0.0037 x --
- Day's Range
0.0036 - 0.0036 - 52 Week Range
0.0002 - 0.0068 - Volume
10,000 - Avg. Volume
281 - Market Cap (intraday)
18.884M - Beta (5Y Monthly) 0.68
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date Aug 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
alteritytherapeutics.comRecent News: PRNAF
View MoreResearch Reports: PRNAF
View MorePerformance Overview: PRNAF
Trailing total returns as of 10/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PRNAF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PRNAF
View MoreValuation Measures
Market Cap
10.58M
Enterprise Value
2.19M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.03
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-52.66%
Return on Equity (ttm)
-104.47%
Revenue (ttm)
4.02M
Net Income Avi to Common (ttm)
-19.12M
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
12.64M
Total Debt/Equity (mrq)
1.15%
Levered Free Cash Flow (ttm)
-5.36M